Life Science News

Distinguished 40 Year International Banker and Former Ernst & Young Partner

Applied UV, Inc. (NasdaqCM: AUVI ) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that Joseph (Jos) Luhukay has joined the Board of Directors. Jos Luhukay joins Applied UV's extensive Executive leadership team and Board as the Company continues the global market expansion of its patented, disruptive, and highly effective suite of fixed and mobile air purification solutions (Airocide and Scientific Air).

This press release features multimedia. View the full release here:

(Graphic: Business Wire)

(Graphic: Business Wire)

Jos Luhukay is a seasoned international banking Executive with over 40 years of experience leading many of Indonesia's leading financial institutions and a former Ernst and Young Partner who led the business advisory and risk consulting practice which provided services in corporate governance, risk management, information systems audit and advisory, internal audit and policy and operational process development. Jos Luhukay's distinguished career brings Applied UV a strong track record in delivering profitable growth for internationally recognized bank and investment banking companies including: Chief Operating Officer of Bank Niaga, Bahana Pembinaan Usaha Indonesia, a main Indonesian Government-owned investment Bank, Chief Operating Officer & Executive Director of the Jakarta Initiative Task Force (set up by the Ministry of Finance) where he managed a $65B portfolio and restructured over 20% of it in less than 2 years, President Director of Bank Lippo, where he was awarded "CEO of the Year" in 2006 by SWA Magazine (the largest business magazine in Indonesia), Deputy President of Temasek-owned Bank Danamon and his most recent role as President Director of Rabobank International Indonesia, a 30 year old Dutch owned Commercial Bank in Indonesia. Jos Luhukay holds an engineering degree in electrical engineering from the University of Indonesia, a Master's and PhD in Computer Science from the University of Illinois at Urbana-Champaign.

John Andrews, Applied UV's Chief Executive Officer, and Director stated, "We welcome Jos to our Board of Directors. During his distinguished career Jos has demonstrated a track record of providing corporate governance, completing complex financial execution and international regulatory compliance with financial institutions that will complement and broaden our existing Board of Directors. Jos's international business connections throughout Southeast Asia and Europe will prove valuable as we continue our international expansion. Jos's leadership and business acumen will provide additional stewardship as we grow our globally recognized suite of both fixed and mobile air purification solutions and is another confident step we are undertaking, as we execute on our global strategy."

Jos Luhukay stated, "I am truly looking forward to working with the leadership team in bringing forth our advanced air purification technologies throughout the world. Both the health & medical and waste-reduction in food production, transportation and storage sectors will benefit highly from these technologies. Given the global conditions we are in, Applied UV offers timely and highly required solutions internationally."

Both Monica Woo and Jos Luhukay were nominated by majority shareholder and approved at Applied UV's Annual Shareholder Meeting held on May 17th, 2022, replacing Gene Bauer and Joel Kanter. On May 17th, 2022, Alastair Clemow resigned from our Board.

Max Munn, Applied UV President and Director stated, "On behalf of the entire Company, I'd like to thank Gene Bauer, Joel Kanter and Alastair Clemow for their tireless efforts the past two years. The stewardship and leadership they provided to our Board was invaluable and has been instrumental in guiding the Company since our IPO."

About Applied UV

Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's Airocide® air purification devices are research backed, clinically proven and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photo catalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities and homes. SteriLumen's connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location.

For more information about Applied UV, Inc., and its subsidiaries, please visit the following website:

Forward-Looking Statements

The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.

For additional Company Information:
Applied UV Inc.
John F. Andrews
Applied UV Inc., CEO & Director

Brett Maas, Managing Principal
Hayden IR
(646) 536-7331

News Provided by Business Wire via QuoteMedia

Applied UV

Applied UV

Keep reading...Show less
BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy

BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy

  • Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell's prostate cancer program based on the patient's HLA type.
  • Bria-Pros™ is a novel off-the-shelf personalized immunotherapy approach to treating prostate cancer.
  • Waisman Biomanufacturing has entered an agreement with BriaCell to manufacture clinical supplies for BriaCell's anticipated clinical trial in advanced prostate cancer.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, has entered a manufacturing service agreement with Waisman Biomanufacturing at the University of Wisconsin–Madison (Waisman), to manufacture Bria-Pros™, BriaCell's off-the-shelf personalized immunotherapy for prostate cancer, for anticipated use in clinical studies. Waisman is a leading contract manufacturing organization (CMO) with experience in the manufacturing of cellular therapies for clinical trials.

Under the terms of the agreement, Waisman will be responsible for good manufacturing practice (GMP) manufacturing of Bria-Pros™ for anticipated use in clinical studies. Waisman's expert team will be working closely with BriaCell's scientific and product development teams to ensure timely production of Bria-Pros™ in compliance with applicable regulatory requirements by the FDA.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
DGTL Holdings Inc. Reports $1M Contract with a Global Leader in Digital Audio Content

DGTL Holdings Inc. Reports $1M Contract with a Global Leader in Digital Audio Content

Annual Service Contract Extension Valued at $1M CAD Focused on Engagement Labs Premiere Data Analytics PaaS, TotalSocial®

DGTL Holdings Inc. (TSXV: DGTL) ("DGTL" or the "Company") is pleased to announce that its wholly owned subsidiary Engagement Labs Inc. ("Engagement Labs" or the "Subsidiary) has secured an annual multi-service contract with the global leader in premium audio storytelling (i.e. podcasts, audiobooks, etc.). This key account client is a subsidiary of a multinational technology leader that is Nasdaq listed with a market capital of US $1.1 trillion. The agreements includes four prolific new title launch studies and a one (1) year PaaS (Platform-as-a-Service) contract with a total value of nearly $1,000,000 (with options for contract renewal).

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Applied UV Announces MedLine Places Follow-On Order

Applied UV Announces MedLine Places Follow-On Order

Continued Demand Due to Centers for Medicare & Medicaid Services Policy

Strongest Sales Channel in Company History

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
BioHarvest Sciences Inc. Reports Strong Q2 2022 Results with Major Achievements on All Fronts

BioHarvest Sciences Inc. Reports Strong Q2 2022 Results with Major Achievements on All Fronts

  • VINIA® sales orders reached a record high of USD 947k representing 99% growth compared to Q2 2021 and 24% growth compared to Q1 2022
  • BioHarvest reiterates guidance for year-on-year sales orders growth of 2.5-3.5X to reach USD 5M - 7M
  • Started production of VINIA® at new 20 tons/year facility enabling the scaling of VINIA® sales and conversion of current 2 tons/year facility to Cannabis
  • Applied for the Cannabis production license in Israel
  • Unveiled the profile of its unique Cannabis composition triggering serious partnership discussions with several Cannabis Multi State Operators (MSO's) in the US

BioHarvest Sciences Inc. (CSE: BHSC) (OTC PINK: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company") today announced Q2 2022 sales orders of its flagship VINIA® product reached a record high of USD 947k, representing 99% growth compared to the same quarter of last year and 24% growth compared to Q1 2022.

BioHarvest also had a strong quarter in R&D execution, highlighted by a May 12th announcement unveiling the profile of its unique Cannabis biomass composition produced in large-scale industrial bioreactors. BioHarvest also applied for a Cannabis production license in Israel. This quarter also saw the transition to the new 20Tons/year VINIA® facility in Yavneh, Israel which will enable the further scaling of the VINIA® business in the US in H2, 2022 and will deliver significant cost reductions over the next 12 months.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
DGTL Holdings Inc. Reports Strategic Restructure of Wholly Owned Subsidiaries

DGTL Holdings Inc. Reports Strategic Restructure of Wholly Owned Subsidiaries

Restructure to Divest of an Estimated $5M in Liabilities and Annual Operating Expenses and to Reposition DGTL Holdings Inc. for Scalable Revenue Growth, Cashflow Positivity and Accretive M&A

The DGTL Holdings Inc. (TSXV: DGTL) ("DGTL" or the "Company") board of directors reports that the Company has initiated a strategic restructuring of its wholly owned subsidiaries, Hashoff LLC ("Hashoff"") and Engagement Labs Inc. ("Engagement Labs"). The goal of restructuring its subsidiaries is to apply objective third-party financial analysis to current business operations to assess long term viability and to optimize organizational structures. The result of this initiative is an estimated divestiture of $5,000,402[i] in liabilities and operating expenses and a repositioning of the Company for scalable revenue growth, near-term cashflow positivity, and long-term shareholder equity.

On June 1, 2022, Hashoff LLC retained the services of Lindenwood Associates, a New York based strategic development and restructuring firm ("Lindenwood") to assess legal and financial viability as well as Klestadt Winters Jureller Southard & Stevens, LLP ("KWJSS") to provide legal services to Hashoff LLC in connection therewith. The Hashoff LLC restructuring team has completed a thorough and objective viability assessment. After presenting their report, and reviewing the facts, the board voted unanimously to accept the recommendations of Lindenwood to commence a formal orderly wind down and subsequent dissolution of Hashoff LLC in accordance with Section 18-801 of the Delaware Limited Liability Company Act.

The result of the Hashoff LLC wind down is the divestiture of an estimated $1,939,053 in accounts payable and accrued expenses and $572,849 in contingent liabilities from the DGTL Holdings Inc. consolidated balance sheet.[ii] As the initial step towards this financial restructuring project, both of DGTL's wholly owned subsidiaries have been approved for PPP (Paycheck Protection Program) loan forgiveness. PPP loan forgiveness applications were processed by the SBA (Small Business Association) a US federal administration agency that administers small business relief loans (as authorized by s.1106 of the federal CARES Act). Hashoff LLC had $177,000 in PPP loans forgiven and Engagement Labs had $420,000 in loans forgiven totalling $597,000 in interest bearing loans removed from the DGTL Holdings balance sheet.

In addition, by identifying and implementing numerous cost savings and efficiency measures, the new DGTL executive team has produced a 50% reduction in annual operating expenses for Engagement Labs Inc. The financial restructure of Engagement Labs provides a viable entity which will now serve as DGTL's flagship social media subsidiary, with multiple operating business lines. In doing so, Engagement Labs Inc. will expand product and service offerings to include strategy, execution, measurement and distribution solutions to serve DGTL's Fortune 100 clients as a full-service social media PaaS (Platform-as-a-Service).

Therefore, within the first 120 days under the leadership of the new DGTL executive team, the Company has proactively divested over $3,234,743 in current and non-current liabilities and an additional $1,891,500 in annual operating expenses[iii] totalling an estimated first year reduction of $5,000,402 in long term debt and on-going operating expenses. When accounting for the longer-term impact of the significant reduction in annual operating expenses, a continuance of the previous cost structure would continue to increase this total estimate with every future year of on-going operations. Financial improvements will begin to be reflected within the Q1 2023 financial statements (October 30, 2022), and subsequent filings, thereafter.

In summary, the new DGTL executive team is dedicated to restoring fiscal responsibility, accountability and sound corporate governance in order to maximize long term value of shareholder equity. Reducing liabilities and post-restructure operating expenses by an estimated $5,000,402 is a major material improvement to the consolidated financial position of the Company. Moving forward, DGTL is now positioned for scalable revenue growth and accretive M&A with a stronger corporate structure and a viable financial position.

In closing, DGTL will be hosting a video webinar on Wednesday July 6th, 2022, which will include a CEO update on the Company and its current operations and future business interests. The participant details for this meeting are listed below. Availability is limited. Register in advance to secure participation.

July 6th, 2022, 01:00 PM Eastern Time (US and Canada)

Register in advance for this meeting via the link below.

After registering, you will receive a confirmation email containing information about joining the meeting.

For more information, please contact:

DGTL Holdings Inc.
John David A. Belfontaine
Chief Executive Officer, Chairman

Phone: +1 (877) 879-3485


DGTL Holdings Inc.

DGTL Holdings Inc. acquires and accelerates transformative digital media, marketing and advertising software and services companies. DGTL (i.e. Digital Growth Technologies and Licensing) specializes in accelerating fully commercialized enterprise level SaaS (software-as-a service) and PaaS (Platform-as-a-Service) companies entering a rapid growth stage within the sectors of social media, gaming, streaming, OTT and others. In doing so, DGTL is seeking to build full-service operating business lines in each sector complete with content, analytics and distribution solutions. DGTL is seeking new accretive M&A opportunities via a blend of unique capitalization structures. DGTL Holdings Inc. is traded on the Toronto Venture Exchange as "DGTL", the OTCQB exchange as "DGTHF", and the FSE as "A2QB0L". DGTL Holdings Inc. has 44,549,265 common shares issued and outstanding, as of the date of this release. For more information visit:

Engagement Labs

As a wholly owned subsidiary of DGTL Holdings Inc., Engagement Labs is an industry-leading data and analytics firm that provides social intelligence for Fortune 500 brands and companies. Engagement Labs' TotalSocial® platform focuses on the entire social ecosystem by combining powerful online (social media) and offline (word of mouth) data with predictive analytics. Engagement Labs has a proprietary ten-year database of unique brand, industry and competitive intelligence, matched with its cutting-edge predictive analytics that use machine learning and artificial intelligence to reveal the social metrics that increase marketing ROI and top line revenue for its diverse group of enterprise level clients. Engagement Labs Inc. will expand product and service offerings to include strategy, execution, measurement and distribution solutions to serve DGTL's Fortune 100 clients as a full-service social media PaaS (Platform-as-a-Service).

To learn more visit

Lindenwood Associates LLC

Lindenwood Associates is an experienced strategic development and restructuring firm. Lindenwood is led by corporate turnaround and restructuring specialists with progressive expertise leading and managing distressed companies, delivering results in crisis situations, divestitures, and a wide range of corporate development initiatives. Lindenwood leads companies through complex challenges spanning a diverse range of industries to achieve improved strength, value, and growth.

For more information visit


Klestadt Winters Jureller Southard & Stevens (KWJS&S), LLP is a boutique commercial law firm dedicated to providing superior legal services. The firm specializes in the primary areas of practice Corporate Reorganization and Restructuring, Commercial Litigation, Transactions & Finance.

For more information, please visit

This news release contains certain statements that constitute forward-looking statements as they relate to DGTL and its subsidiaries. Forward-looking statements are not historical facts but represent management's current expectation of future events, and can be identified by words such as "believe", "expects", "will", "intends", "plans", "projects", "anticipates", "estimates", "continues" and similar expressions. Although management believes that the expectations represented in such forward-looking statements are accurate, there can be no assurance that they will prove to be correct. By their nature, forward-looking statements include assumptions, and are subject to inherent risks and uncertainties that could cause actual future results, conditions, actions or events to differ materially from those in the forward-looking statements. If and when forward-looking statements are set out in this new release, DGTL will also set out the material risk factors or assumptions used to develop the forward-looking statements. Except as expressly required by applicable securities laws, DGTL assumes no obligation to update or revise any forward-looking statements. The future outcomes that relate to forward-looking statements may be influenced by many factors, including but not limited to the impact of all intangible and variable economic and legal risks that at this time are immeasurable and impossible to define.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Naturally Splendid Reports Year-End Results for 2021

Naturally Splendid Reports Year-End Results for 2021

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N) (TSXV:NSP) (OTC PINK:NSPDF) announces its audited financial results for the year ended December 31, 2021. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid Chief Financial Officer Mr. George Ragogna states, "The company continues to focus on reducing operating overheads while we continue to re-purpose our existing certified food facility in Pitt Meadows, BC to optimize production of plant-based entrees. We have made positive strides for the Company in several areas including securing an exclusive ten (10) year manufacturing and distribution agreement for Canada with Flexitarian Foods Pty. Ltd, Australia's largest plant-based manufacturer. This 10-year exclusive manufacturing agreement can be extended for a further ten (10) year period.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News